



2800 Meridian Parkway, Suite 195
Durham, North Carolina 27713
(919) 313-1180 (phone)
(919) 313-1190 (fax)

Contact:

Paul Boucher
Chief Executive Officer
(919)313-1195
pboucher@parion.com

Parion Sciences Appoints Alison Church, M.D. as Chief Medical Officer

Durham, NC (February 1, 2018) – Parion Sciences, a clinical stage company dedicated to developing novel therapies for the treatment of pulmonary and ocular diseases, today announced the appointment of Alison Church, M.D., as Chief Medical Officer.

“We are excited to welcome Alison to the Parion team as our Chief Medical Officer,” said Paul Boucher, President and CEO, Parion. “Her leadership and diverse clinical experience will be critical in strengthening our clinical development efforts and supporting the overall progress of our portfolio of respiratory and topical programs.”

Dr. Church joins Parion from GlaxoSmithKline where she most recently served as Head Physician of the Dermatology Unit. In addition, she previously held other senior roles at GSK, leading the development across numerous respiratory therapies, including the global submissions and approvals of Anoro[®] and Incruse[®] as treatments for COPD patients.

Dr. Church holds an M.D. from Columbia University. She completed her pediatric residency training at Morgan Stanley Children’s Hospital of New York and her fellowship training in allergy/immunology at Duke University. She maintains board certifications in both Pediatrics and Allergy/Immunology.

About Parion Sciences

Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at www.Parion.com.